Labnovation offers a fully integrated solution that combines the company's comprehensive AD blood-based biomarker assay kits — covering the complete "A+T+N" panel (Aβ1-40, Aβ1-42, GFAP, p-Tau181, and p-Tau217) — with the fully automated chemiluminescence immunoassay (CLIA) platform, the BG-DTi2000. This turnkey system delivers high-sensitivity, high-throughput, and rapid-result testing for Alzheimer's disease early screening, differential diagnosis, and therapeutic monitoring — all from a simple peripheral blood sample.